Elevated neurofilament levels in neurological diseases

Brain Research

Volumn 987, Issue 1, 2003, Pages 25-31

  Norgren, Niklas ^a   Rosengren, Lars ^b   Stigbrand, Torgny ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cerebrospinal fluid; ELISA; Neurodegenerative disease; Neurofilament protein

Indexed keywords

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANALYTIC METHOD; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRAPYRAMIDAL SYMPTOM; LIGHT; MEASUREMENT; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; NEUROFILAMENT; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; SENSITIVITY ANALYSIS;

EID: 0142011171     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)03219-0     Document Type: Article

References (38)

1. Aurell A., Rosengren L.E., Karlsson B., Olsson J.E., Zbornikova V., Haglid K.G. Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction. Stroke. 22:1991;1254-1258.
2. Beaulieu J.M., Jacomy H., Julien J.P. Formation of intermediate filament protein aggregates with disparate effects in two transgenic mouse models lacking the neurofilament light subunit. J. Neurosci. 20:2000;5321-5328.
3. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol. 26:1995;231-245.
4. Bornstein N.M., Aronovich B., Korczyn A.D., Shavit S., Michaelson D.M., Chapman J. Antibodies to brain antigens following stroke. Neurology. 56:2001;529-530.
5. Brooks B.R. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial Clinical limits of amyotrophic lateral sclerosis workshop contributors. J. Neurol Sci. 124:(Suppl):1994;96-107.
6. Couratier P., Yi F.H., Preud'homme J.L., Clavelou P., White A., Sindou P., Vallat J.M., Jauberteau M.O. Serum autoantibodies to neurofilament proteins in sporadic amyotrophic lateral sclerosis. J. Neurol Sci. 154:1998;137-145.
7. Elder G.A., Friedrich V.L. Jr., Bosco P., Kang C., Gourov A., Tu P.H., Lee V.M., Lazzarini R.A. Absence of the mid-sized neurofilament subunit decreases axonal calibers, levels of light neurofilament (NF-L), and neurofilament content. J. Cell. Biol. 141:1998;727-739.
8. Gearing M., Olson D.A., Watts R.L., Mirra S.S. Progressive supranuclear palsy: neuropathologic and clinical heterogeneity. Neurology. 44:1994;1015-1024.
9. Geisler N., Weber K. Self-assembly in Vitro of the 68 000 molecular weight component of the mammalian neurofilament triplet proteins into intermediate-sized filaments. J. Mol. Biol. 151:1981;565-571.
10. Herrmann M., Vos P., Wunderlich M.T., de Bruijn C.H., Lamers K.J. Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke. 31:2000;2670-2677.
11. Hesse C., Rosengren L., Vanmechelen E., Vanderstichele H., Jensen C., Davidsson P., Blennow K. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J. Alzheimer's Dis. 2:2000;199-206.
12. Hoffman P.N., Cleveland D.W., Griffin J.W., Landes P.W., Cowan N.J., Price D.L. Neurofilament gene expression: a major determinant of axonal caliber. Proc. Natl. Acad. Sci. USA. 84:1987;3472-3476.
13. Holmberg B., Johnels B., Ingvarsson P., Eriksson B., Rosengren L. CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes. Parkinsonism Relat. Disord. 8:2001;23-31.
14. Hughes A.J., Daniel S.E., Blankson S., Lees A.J. A clinicopathologic study of 100 cases of Parkinson's disease. Arch. Neurol. 50:1993;140-148.
15. Julien J.P., Mushynski W.E. Neurofilaments in health and disease. Prog. Nucleic Acid. Res. Mol. Biol. 61:1998;1-23.
16. Karlsson J.E., Rosengren L.E., Haglid K.G. A rapid HPLC method to separate the triplet proteins of neurofilament. J. Neurochem. 49:1987;1375-1378.
17. Karlsson J.E., Rosengren L.E., Haglid K.G. Quantitative and qualitative alterations of neuronal and glial intermediate filaments in rat nervous system after exposure to 2,5-hexanedione. J. Neurochem. 57:1991;1437-1444.
18. Kriz J., Zhu Q., Julien J.P., Padjen A.L. Electrophysiological properties of axons in mice lacking neurofilament subunit genes: disparity between conduction velocity and axon diameter in absence of NF-H. Brain Res. 885:2000;32-44.
19. Kuroki M. A simple solid-phase competition assay with labeled antigen. Morris G.E. Methods in Molecular Biology. Vol. 66:1996;47-54 Humana Press, New Jersey.
20. Lee M.K., Xu Z., Wong P.C., Cleveland D.W. Neurofilaments are obligate heteropolymers in vivo. J. Cell. Biol. 122:1993;1337-1350.
21. Lycke J.N., Karlsson J.E., Andersen O., Rosengren L.E. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 64:1998;402-404.
22. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:1984;939-944.
23. Norgren N., Karlsson J.E., Rosengren L., Stigbrand T. Monoclonal antibodies selective for low molecular weight neurofilaments. Hybrid Hybridomics. 21:2002;53-59.
24. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
25. Rao M.V., Houseweart M.K., Williamson T.L., Crawford T.O., Folmer J., Cleveland D.W. Neurofilament-dependent radial growth of motor axons and axonal organization of neurofilaments does not require the neurofilament heavy subunit (NF-H) or its phosphorylation. J. Cell. Biol. 143:1998;171-181.
26. Roman G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., Amaducci L., Orgogozo J.M., Brun A., Hofman A., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 43:1993;250-260.
27. Rosengren L.E., Karlsson J.E., Karlsson J.O., Persson L.I., Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J. Neurochem. 67:1996;2013-2018.
28. Rosengren L.E., Karlsson J.E., Sjogren M., Blennow K., Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology. 52:1999;1090-1093.
29. Semra Y.K., Seidi O.A., Sharief M.K. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J. Neuroimmunol. 122:2002;132-139.
30. Silber E., Semra Y.K., Gregson N.A., Sharief M.K. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology. 58:2002;1372-1381.
31. Sjogren M., Blomberg M., Jonsson M., Wahlund L.O., Edman A., Lind K., Rosengren L., Blennow K., Wallin A. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J. Neurosci. Res. 66:2001;510-516.
32. Sjogren M., Davidsson P., Wallin A., Granerus A.K., Grundstrom E., Askmark H., Vanmechelen E., Blennow K. Decreased CSF-β-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of β-amyloid induced by disparate mechanisms. Dement. Geriatr. Cogn. Disord. 13:2002;112-118.
33. Sjogren M., Rosengren L., Minthon L., Davidsson P., Blennow K., Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology. 54:2000;1960-1964.
34. Studahl M., Rosengren L., Gunther G., Hagberg L. Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction. J. Neurol. 247:2000;636-642.
35. Weber K., Shaw G., Osborn M., Debus E., Geisler N. Neurofilaments, a subclass of intermediate filaments: structure and expression. Cold Spring Harb. Symp. Quant. Biol. 48:(Pt 2):1983;717-729.
36. Wenning G.K., Tison F., Ben Shlomo Y., Daniel S.E., Quinn N.P. Multiple system atrophy: a review of 203 pathologically proven cases. Mov. Disord. 12:1997;133-147.
37. Zemlan F.P., Rosenberg W.S., Luebbe P.A., Campbell T.A., Dean G.E., Weiner N.E., Cohen J.A., Rudick R.A., Woo D. Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J. Neurochem. 72:1999;741-750.
38. Zhu Q., Couillard-Despres S., Julien J.P. Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments. Exp. Neurol. 148:1997;299-316.